Venetoclax, another BCL2-inhibitor, combined with a TKI reduces the serial re-engraftment capacity of CML LSCs in mice compared with a TKI alone [118]. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.